This is a phase IIb clinical trial to evaluate the safety and immunogenicity of Ad5-nCoV developed by Cansino and Beijing Institute of Biotechnology in health people aged 6 years old and above.
The study will be a double-blind, placebo-controlled trial with participants randomly allocated 2:1 to placebo and experimental vaccine.
The immunization schedule is two doses intramuscular injections (deltoid).